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Since the seminal studies by Fialkow et al. in the seventies
[1] and by Bonnet and Dick in the nineties [2], where an
organized tumor cell hierarchy originating from transformed
hematopoietic stem cells was found inmyeloid leukemias, the
cancer stem cell (CSC) model of tumor development drew
the attention of the scientific community and became the
focus of extensive discussion. This theme gained momentum
over the past decade, with the identification of stemlike cells
as drivers of tumor initiation, recurrence, and metastasis
spread in a variety of nonhematopoietic human cancers.
These characteristics postulated them as novel and promising
therapeutic targets for cancer, especially in the context of
drug-resistant tumors [3].
The origin of these stemlike cells is being extensively
studied. In some types of tumors, such as in blood, brain,
colon, and skin cancer, it has been shown that adult stem
cells are prone to transformation due to a longer half-life
within tissues compared to their cell progenies, facilitating
the accumulation of oncogenic mutations as a result of
prolonged exposure to genotoxic stresses [4]. In other cases,
de novo acquisition of stem cell properties may occur in
either normal or neoplastic cells due to genetic/epigenetic
aberrations [5]. Finally, the CSC model has been put forward
to explain why tumors like breast cancer might return years
after surgery. In this situation, lower proliferation rate might
allow cells to escape from aggressive therapy and allow for
genetic/epigenetic evolution.
Advances in the field, however, point to varied and
more complexmodels of tumor development than previously
envisioned, in which the stemlike phenotype may also be
dynamically acquired by cancer cells through interaction
with stromal cells and soluble factors [6]. A relevant question
timely addressed in this special issue is the understanding of
the contribution of resident stem cells to the tumor microen-
vironment (TME). This is of major relevance since they
may significantly influence tumor progression, aggressive-
ness, and response to therapy. The contribution of pericytes
to tumor growth, angiogenesis, metastasis, and evasion of
immune destruction, which are classic hallmarks of cancer,
is comprehensively reviewed by A. L. Ribeiro and O. K.
Okamoto. In their article, the authors also discuss a pericyte-
mediated regulation of stemness properties in cancer cells
and argue in favor of pericytes as cellular targets for new
cancer therapies aiming at the TME. Indeed, many new anti-
cancer therapies targeting the TME are under development,
with currently approved antiangiogenic drugs as examples of
such strategy. However, events of tumor recurrence and poor
response to antiangiogenic therapy still puzzle researchers
and emphasize the need for continuous studies. In the article
by M. Marc¸ola and C. E. Rodrigues, the involvement of
endothelial progenitor cells in tumor angiogenesis is critically
reviewed. In their article, the specific roles of different
members of the VEGF family of growth factors, as well as the
relevance of the vascular niche to stemness in cancer cells, are
also carefully discussed.
Another practical issue of clinical relevance is the rigor-
ous evaluation of potential oncogenic risks associated with
stem cell therapy. Long-term safety issues must be properly
addressed before stem cell-based therapies enter clinical
trials, but such studies are outnumbered in the literature by
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studies evaluating therapeutic effects based on restoration of
tissue integrity and physiological balance. While the original
article by T. Jazedje et al. addresses this issue at the preclinical
stage, showing in a murine breast adenocarcinoma model
that mesenchymal stromal cells (MSC) may exert either pro-
or antitumorigenic effects depending on the experimental
condition, R. Schweizer et al. bring amore clinical perspective
to this issue, presenting an interesting discussion about
the possible oncogenic hazards of adipose-derived MSC in
breast cancer patients subjected to breast reconstruction after
mastectomy.
Finally, due to their tumor homing properties, the use
of stem cells as vehicles to deliver suicide genes is a strategy
highly pursued in cancer gene therapy. However, low delivery
efficiency and off-target effects are common limitations of
current expression systems. In the original article by Y. Luo
et al., the authors elegantly characterize a novel inducible
transgene expression system based on the action of neural
stem cells that could be further explored to treat malignant
gliomas.
In summary, the articles compiled in this special issue
highlight how the growing investigation of tumor develop-
ment through the lens of stem cell biologists is significantly
impacting basic and translational cancer research.This inter-
play between stem cell and tumor biology offers an excep-
tional opportunity to improve our knowledge about cancer,
one of the leading causes of death worldwide. Advances in
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